Table 1 Patient characteristics by anti-fibrotic use and by specific medication
Characteristic: count, mean (SD) or Frequency (%) | IPF patients, n = 1218 | Using an anti-fibrotic, n = 703 | ||
|---|---|---|---|---|
No anti-fibrotic use (n = 478) | Anti-fibrotic use (n = 740) | Nintedanib (n = 312) | Pirfenidone (n = 391) | |
Demographics | ||||
 Age | 70.8 (8.6) | 70.2 (7.6) | 69.9 (7.3) | 70.6 (7.7) |
 Male | 358 (74.9) | 563 (76.1) | 238 (76.3) | 302 (77.2) |
 Race: White | 432 (90.4) | 695 (93.9) | 288 (92.3) | 373 (95.4) |
  Black or African American | 7 (1.5) | 11 (1.5) | 6 (1.9) | 5 (1.1) |
  Asian and other | 39 (8.2) | 34 (4.6) | 18 (5.8) | 13 (3.3) |
 Insurance: Private | 248 (51.9) | 385 (52.0) | 167 (53.5) | 197 (50.4) |
  Medicare | 181 (37.8) | 284 (38.4) | 116 (37.2) | 153 (39.1) |
  Medicaid | 7 (1.5) | 10 (1.4) | 4 (1.3) | 5 (1.3) |
  Medicare-Medicaid | 1 (0.2) | 1 (0.1) | 0 (0) | 1 (0.2) |
  Military | 6 (1.3) | 6 (0.8) | 4 (1.3) | 2 (0.5) |
  Other/none/unknown | 35 (7.3) | 54 (7.3) | 21 (6.7) | 33 (7.5) |
Medical History | ||||
 COPD | 39 (8.3) | 59 (8.0) | 31 (10.1) | 25 (6.4) |
 Pulmonary hypertension | 23 (4.9) | 48 (6.5) | 14 (4.6) | 31 (8.0) |
 GERD | 79 (16.5) | 129 (17.5) | 61 (19.6) | 59 (15.1) |
 Obstructive sleep apnea | 109 (22.8) | 211 (28.5) | 85 (27.0) | 117 (29.9) |
 Coronary artery disease | 107 (22.8) | 194 (26.4) | 68 (22.1) | 118 (30.3) |
 Smoking – current or previous | 301 (63.0) | 475 (64.3) | 195 (62.5) | 254 (65.1) |
Clinical Characteristics | ||||
 Days since diagnosis | 772.0 (1009.3) | 1001.2 (927.3) | 879.0 (886.2) | 1088.4 (929.4) |
 Multidisciplinary conference | 207 (43.4) | 312 (42.2) | 135 (43.3) | 163 (41.8) |
 Oxygen use | 147 (30.8) | 371 (50.1) | 148 (47.4) | 198 (50.4) |
 Pulmonary rehabilitation | 67 (14.0) | 219 (29.6) | 93 (29.8) | 108 (27.6) |
 6-min walk distance (m, mean SD) | 377.8 (156.7) | 357.2 (136.7) | 363.6 (138.1) | 354.2 (136.9) |
 FVC (percent-predicted, mean SD) | 71 (18) | 68 (17) | 67 (17) | 69 (17) |
 FVC categorical: >  90% | 59 (12.3) | 71 (9.6) | 31 (9.9) | 40 (10.2) |
  50 to < 90% | 328 (68.6) | 527 (71.2) | 220 (70.5) | 278 (71.1) |
   < 50% | 47 (9.8) | 107 (14.5) | 43 (13.8) | 58 (14.8) |
 DLCO (percent-predicted, mean SD) | 45 (17) | 40 (17) | 38 (16) | 41 (18) |
 DLCO categorical: > 90% | 8 (1.7) | 8 (1.1) | 3 (1.0) | 5 (1.3) |
  80 to < 90% | 7 (1.5) | 4 (0.5) | 1 (0.3) | 3 (0.8) |
  30 to < 80% | 310 (64.9) | 470 (63.5) | 186 (59.6) | 265 (67.8) |
   < 30% | 67 (14.0) | 181 (24.5) | 81 (26.0) | 84 (21.5) |
 Fatigue severity scale (mean, SD) | 4.1 (1.8) | 4.3 (1.7) | 4.2 (1.7) | 4.2 (1.7) |
 Leicester cough score (mean, SD) | 16.8 (3.5) | 16.4 (3.6) | 16.6 (3.7) | 16.4 (3.5) |
 SF-6D score (mean, SD) | 0.7 (0.1) | 0.7 (0.1) | 0.7 (0.1) | 0.7 (0.1) |
 UCSD shortness of breath score (mean, SD) | 37.7 (26.8) | 42.4 (25.2) | 41.8 (24.4) | 42.5 (25.8) |
 Anticoagulant use | 43 (9.0) | 79 (10.7) | 21 (6.7) | 51 (13.0) |
 Immunomodulatory medication use | 124 (26.0) | 150 (20.3) | 70 (22.4) | 71 (18.2) |
 Clinical trial participation in last 12mo. | 42 (8.8) | 123 (16.6) | 30 (9.7) | 90 (23.0) |